MULTISPECTRAL FLUORESCENT PROTEINS

Information

  • Research Project
  • 2750064
  • ApplicationId
    2750064
  • Core Project Number
    R44GM053287
  • Full Project Number
    5R44GM053287-03
  • Serial Number
    53287
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1995 - 29 years ago
  • Project End Date
    7/31/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/1998 - 26 years ago
  • Budget End Date
    7/31/2000 - 24 years ago
  • Fiscal Year
    1998
  • Support Year
    3
  • Suffix
  • Award Notice Date
    7/20/1998 - 26 years ago
Organizations

MULTISPECTRAL FLUORESCENT PROTEINS

High through-put mutagenesis and screening methods were developed during Phase 1 for isolating spectral and kinetic variants of the Green Fluorescent Protein (GFP). Mutants were found which show large spectral shifts and accelerated fluorophore formation relative to wild-type. Optical screening of approximately 500,000 combinatorial mutants near the chromophore site yielded two main classes of proteins with blue- shifted emission (BFP) or red-shifted excitation (RSGFP). By shifting the excitation maximum from 390 to 490 nm, the RSGFP spectrum is well separated from cellular autofluorescence, making it vastly superior to wild-type GFP for epifluorescence microscopy and fluorescence activated cell sorting (FACS). In Phase 2, we plan to search for red-shifted emission derivatives of RSGFP using a method capable of negotiating very rough fitness landscapes. RSGFP and a red-shifted emission derivative would constitute an extremely valuable pair of molecular reagents, making two channel FACS, dual color epifluorescence microscopy, and fluorescence resonance energy transfer measurements readily available to cell biologists. In conjunction with imaging spectroscopy, the construction of a series of spectroscopically distinct red-shifted emission derivatives (e.g., green, yellow, orange, and red) would enable simultaneous analysis of several tagged promoters, fusion proteins, and/or cell types. PROPOSED COMMERCIAL APPLICATION The isolation of a red-emitting derivative of the green Fluorescent Protein will constitute a highly visible flagship product for our company. From the standpoint of Phase 3 commercialization, this will result in: 1) direct sales of these molecular reagents (about $8,000,000 gross), 2) revenues from licensing composition of matter patent rights, 3) enhanced sales of imaging spectrophotometers, 4) an increase in in- house imaging contracts, and 5) enhanced sales of KAIROS' protein engineering software.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    KAIROS SCIENTIFIC, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES